- Home
- DLXY vs SNSE Comparison
DLXY vs SNSE Comparison
Compare DLXY & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLXY
- SNSE
- Stock Information
- Founded
- DLXY 2007
- SNSE 2005
- Country
- DLXY Singapore
- SNSE United States
- Employees
- DLXY N/A
- SNSE N/A
- Industry
- DLXY
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- DLXY
- SNSE Health Care
- Exchange
- DLXY Nasdaq
- SNSE Nasdaq
- Market Cap
- DLXY 13.9M
- SNSE 14.5M
- IPO Year
- DLXY 2025
- SNSE 2021
- Fundamental
- Price
- DLXY $1.07
- SNSE $9.17
- Analyst Decision
- DLXY
- SNSE Strong Buy
- Analyst Count
- DLXY 0
- SNSE 5
- Target Price
- DLXY N/A
- SNSE $72.50
- AVG Volume (30 Days)
- DLXY 223.3K
- SNSE 79.1K
- Earning Date
- DLXY 11-13-2025
- SNSE 11-07-2025
- Dividend Yield
- DLXY N/A
- SNSE N/A
- EPS Growth
- DLXY N/A
- SNSE N/A
- EPS
- DLXY 0.07
- SNSE N/A
- Revenue
- DLXY $314,916,000.00
- SNSE N/A
- Revenue This Year
- DLXY N/A
- SNSE N/A
- Revenue Next Year
- DLXY N/A
- SNSE N/A
- P/E Ratio
- DLXY $15.61
- SNSE N/A
- Revenue Growth
- DLXY 8.90
- SNSE N/A
- 52 Week Low
- DLXY $0.64
- SNSE $5.00
- 52 Week High
- DLXY $7.16
- SNSE $18.35
- Technical
- Relative Strength Index (RSI)
- DLXY N/A
- SNSE 44.10
- Support Level
- DLXY N/A
- SNSE $9.07
- Resistance Level
- DLXY N/A
- SNSE $12.40
- Average True Range (ATR)
- DLXY 0.00
- SNSE 2.09
- MACD
- DLXY 0.00
- SNSE -0.44
- Stochastic Oscillator
- DLXY 0.00
- SNSE 8.37
About DLXY Delixy Holdings Limited Ordinary Shares
Delixy Holdings Ltd a holding company that operates through subsidiary. It is engaged in the trading of oil-related products, which can be categorized into crude oil, and oil-based products such as naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. The company has two reportable segments: the Sale of crude oil and the Sale of oil-based products. Key revenue is generated from the Sale of crude oil.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).